International Clinical Trial: Adebrelimab combined with NALIRIFOX for neoadjuvant therapy of resectable pancreatic cancer

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133371) titled 'Adebrelimab combined with NALIRIFOX for neoadjuvant therapy of resectable pancreatic cancer' on Sept. 24.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University

Condition: Resectable pancreatic cancer (RPC)

Intervention: Arm A:Preoperative adebelimab + irinotecan liposome + oxaliplatin + 5-FU/LV Arm B:Preoperative irinotecan liposome + oxaliplatin + 5-FU/LV

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2024-04-22

Target Sample Size: Arm A:60;Arm B:60;Arm C:60;

Countries of Recruitment: Ch...